Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
International AIDS Vaccine Initiative
ClinicalTrials.gov Identifier:
NCT01264445
First received: December 20, 2010
Last updated: February 8, 2013
Last verified: February 2013
  Purpose

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an adjuvanted GSK investigational HIV vaccine and Ad35-GRIN in 4 different regimens at months 1, 2, 3, and 4.


Condition Intervention Phase
HIV Infections
Biological: Adjuvanted GSK investigational HIV vaccine formulation 1
Biological: Adjuvanted GSK investigational HIV vaccine formulation 2
Biological: Ad35 investigational HIV vaccine
Biological: Placebo (saline)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase I Double-blinded, Placebo-controlled, Randomized Trial in HIV-uninfected, Healthy Adult Volunteers to Evaluate the Safety and Immunogenicity of an Adjuvanted GSK HIV Vaccine Administered With Ad35-GRIN Investigational Vaccine

Resource links provided by NLM:


Further study details as provided by International AIDS Vaccine Initiative:

Primary Outcome Measures:
  • Safety of an adjuvanted HIV protein vaccine in prime-boost combinations with AD35-GRIN or coadministered with AD35-GRIN [ Time Frame: 16 months ] [ Designated as safety issue: Yes ]
    Safety of an adjuvanted (dose escalation for adjvans) HIV protein vaccine given as prime or boost in combination with Ad35-GRIN or co-administered with Ad35-GRIN


Secondary Outcome Measures:
  • Immunogenicity of an adjuvanted HIV protein vaccine given in different prime-boost regimens with Ad35-GRIN or coadminisitered with Ad35-GRIN [ Time Frame: 16 months ] [ Designated as safety issue: No ]

Enrollment: 147
Study Start Date: February 2011
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
Biological: Adjuvanted GSK investigational HIV vaccine formulation 1
Receive at Months 0 and 1
Biological: Ad35 investigational HIV vaccine
Receive at Month 4
Biological: Placebo (saline)
(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
Experimental: Group B
Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
Biological: Adjuvanted GSK investigational HIV vaccine formulation 2
Receive at Months 0 and 1
Biological: Ad35 investigational HIV vaccine
Receive at Month 4
Biological: Placebo (saline)
(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
Experimental: Group C
Ad35-GRIN investigational HIV vaccine at Month 0 followed by Adjuvanted GSK investigational HIV vaccine at Months 3 and 4.
Biological: Ad35 investigational HIV vaccine
Receive at Month 0
Biological: Adjuvanted GSK investigational HIV vaccine formulation 2
Receive at Months 3 and 4
Biological: Placebo (saline)
(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
Experimental: Group D
Adjuvanted GSK investigational HIV vaccine and Ad35-GRIN investigational HIV vaccine co-administered (simultaneous administration with separate injections)at Months 0, 1, and 4.
Biological: Adjuvanted GSK investigational HIV vaccine formulation 2
Receive at Months 0, 1, and 4
Biological: Ad35 investigational HIV vaccine
Receive at Months 0, 1, and 4
Biological: Placebo (saline)
(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)

Detailed Description:

Volunteers will be screened up to 42 days before vaccination (up to 90 days for Ad35 neutralizing antibody) and will be followed for 12 months after the last vaccination (16 months total participation).

It is estimated that it will take approximately 5 months to complete enrolment.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy males and females, as assessed by a medical history, physical exam, and laboratory tests
  2. At least 18 years of age on the day of screening and has not reached his/her 41st birthday on the day of first vaccination
  3. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study (screening plus 16 months)
  4. In the opinion of the Principal Investigator or designee and based on Assessment of Informed Consent Understanding results, has understood the information provided and potential risks linked to vaccination and participation in the trial. Written informed consent needs to be provided by the volunteer before any study-related procedures are performed
  5. Willing to undergo HIV testing, risk reduction counselling, receive HIV test results and committed to maintaining low risk behaviour for the trial duration
  6. If a female of childbearing potential (not menopausal or anatomically sterile), willing to use an effective non-barrier method of contraception (hormonal contraceptive; intra-uterine device), from screening until four months after last vaccination. All female volunteers must be willing to undergo urine pregnancy tests at time points as indicated in the study protocol and must test negative prior to each vaccination.
  7. If sexually active male (who is not anatomically sterile), willing to use an effective method of contraception (such as consistent condom use) from the day of first vaccination until 4 months after the last vaccination
  8. Willing to forgo donations of blood or any other tissues during the study and, for those who test HIV positive after vaccination, until the anti-HIV antibody titres become undetectable

Exclusion Criteria:

  1. Confirmed HIV-1 or HIV-2 infection
  2. Any clinically relevant abnormality on history or examination including history of immunodeficiency, malignancy or autoimmune disease; use of systemic corticosteroids (<2 weeks use of topical or inhaled steroids is permitted); immunosuppressive, anticancer, anti-tuberculosis or other medications considered significant by the investigator within the previous 6 months
  3. Any clinically significant acute or chronic medical condition that is considered progressive, or in the opinion of the investigator, makes the volunteer unsuitable for participation in the study
  4. Detection of Ad35-specific serum neutralizing antibody
  5. Reported high-risk behaviour for HIV infection within 6 months prior to first vaccination, as defined by the protocol.
  6. If female, pregnant or planning a pregnancy within 4 months after last vaccination; or lactating
  7. Unstable asthma (e.g. sudden acute attacks occurring without an obvious trigger) or asthma requiring:

    • Daily steroid or long acting beta-agonist prevention
    • Hospitalization in the last two years
  8. Bleeding disorder that was diagnosed by a physician e.g., factor deficiency, coagulopathy or platelet disorder that requires special precautions. (A volunteer who states that he or she has easy bruising or bleeding, but does not have a formal diagnosis and has intramuscular (IM) injections and blood draws without any adverse experience is eligible)
  9. History of splenectomy
  10. Any abnormal laboratory parameters as defined by the protocol;
  11. Receipt of live-attenuated vaccine within the previous 60 days (live attenuated flu vaccine within 14 days) or planned receipt within 60 days after vaccination with Investigational Product; or receipt of other vaccine (e.g. pneumococcal), allergy treatment with antigen injections or tuberculin skin test within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product
  12. Receipt of blood transfusion or blood-derived products within the previous 6 months
  13. Participation in another clinical trial of an Investigational Product currently, within the previous 3 months or expected participation during this study
  14. Prior receipt of another investigational HIV vaccine candidate (note: receipt of an HIV vaccine placebo will not exclude a volunteer from participation if documentation is available and the IAVI Medical Monitor gives approval)
  15. History of severe local or systemic reactogenicity to vaccines (e.g. anaphylaxis, respiratory difficulty, angioedema)
  16. History of severe allergic reactions to any substance requiring hospitalization or emergency medical care (e.g. Steven-Johnson syndrome, bronchospasm or hypotension)
  17. Known sensitivity to sulphite, aspirin or aminoglycoside antibiotics (e.g. amikacin, arbekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, etc)
  18. Confirmed diagnosis of active hepatitis B (HBsAg), hepatitis C (HCV antibodies), active syphilis or active tuberculosis
  19. History of severe neurological disorder, seizure or psychiatric disorder (e.g schizophrenia, severe psychosis, bipolar disorder requiring therapy, suicidal attempt or ideation)
  20. For those volunteers at clinical centres participating in ophthalmic examinations, any clinically significant abnormality found on baseline ophthalmic examination.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01264445

Locations
Kenya
Kenya AIDS Vaccine Initiative
Nairobi, Kenya
Uganda
Uganda Virus Research Institute-IAVI
Entebbe, Uganda
Medical Research Council
Masaka, Uganda
Zambia
Zambia-Emory HIV Research Project
Lusaka, Zambia
Sponsors and Collaborators
International AIDS Vaccine Initiative
GlaxoSmithKline
Investigators
Principal Investigator: Gloria S Omosa-Manyonyi, MBChB,DPH,DLSHTM, MSc. Kenya AIDS Vaccine Initiative
Principal Investigator: Juliet Mpendo, MBChB, MPH Uganda Virus Research Institute-IAVI
Principal Investigator: Eugene Ruzagira, MBChB MPH Medical Research Council-UVRI Uganda Research Unit on AIDS
Principal Investigator: Elwyn Chomba, BSc, MBChB, DCH, MRCP Zambia Emory HIV Research Project
  More Information

Additional Information:
No publications provided

Responsible Party: International AIDS Vaccine Initiative
ClinicalTrials.gov Identifier: NCT01264445     History of Changes
Other Study ID Numbers: IAVI B002
Study First Received: December 20, 2010
Last Updated: February 8, 2013
Health Authority: United States: Food and Drug Administration
Uganda: Uganda Virus Research Institute, Science and Ethics Committee (UVRI SEC)
Uganda: National Drug Authority
Uganda: Pharmacy and Poisons Board
Kenya: Kenyatta National Hospital/University of Nairobi Ethics and Research Committee
Kenya: National Council for Science and Technology (NCST)
Zambia: University of Zambia Biomedical Research Ethics Committee (UNZAREC)
Zambia: Emory Institutional Review Board
Zambia: Pharmacy Regulatory Authority
Zambia: Ministry of Health

Keywords provided by International AIDS Vaccine Initiative:
HIV

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on April 16, 2014